首页|Prognostic differences of refractory/relapsed nodal and extranodal diffuse large B-cell lymphoma in the chimeric antigen receptor T cell therapy era

Prognostic differences of refractory/relapsed nodal and extranodal diffuse large B-cell lymphoma in the chimeric antigen receptor T cell therapy era

扫码查看
原文链接
  • NSTL
  • Elsevier
Background: Extranodal involvement is recognized as a poor prognostic factor for diffuse large B-cell lymphoma (DLBCL). However, the prognostic differences of patients with refractory/relapsed (R/R) nodal and extranodal DLBCL in the chimeric antigen receptor T cell (CART) therapy era are still unclear. Materials and methods: In this study, 18 R/R nodal DLBCL (R/R N-DLBCL) and 19 R/R extranodal DLBCL (R/R EN-DLBCL) were enrolled to compare clinical outcomes. Results: The median follow-up time was 13 (range, 1-47) months and one-year progression-free survival (PFS; 83.3% vs. 42.1%, P = 0.008) and one-year overall survival (OS; 94.4% vs. 63.2%, P = 0.020) were significantly different between nodal and extranodal patients. In the multivariable Cox regression analysis, R/R EN-DLBCL was associated with worse PFS (hazard ratio [HR] = 4.263, P = 0.018) and OS (HR = 9.589, P = 0.034) compared to R/R N-DLBCL. Additionally, autologous hematopoietic stem cell transplantation (ASCT) combined with CART therapy (ASCT + CART) was correlated with better PFS (HR = 0.164, P = 0.003) compared to CART treatment alone. Conclusions: The clinical outcomes of R/R EN-DLBCL were worse than R/R N-DLBCL in patients receiving CART therapy and ASCT + CART therapy is a promising alternative treatment for patients with R/R EN-DLBCL.

Refractoryrelapsed nodal diffuse large B-celllymphomarelapsed extranodal diffuse large B-cell lymphomaCD19 chimeric antigen receptor T cell therapyAutologous hematopoietic stem celltransplantationPrognosisHODGKIN-LYMPHOMARITUXIMAB ERAINVOLVEMENTSITES

Song, Zhiqiang、Xu, Lili、Tang, Gusheng、Gao, Lei、Wang, Libing、Ni, Xiong、Chen, Li、Chen, Jie、Wang, Tao、Feng, Dongge、Yu, Xuejun、Yang, Jianmin、Wang, Yang

展开 >

Inst Hematol,Second Mil Med Univ

HuaDao Biopharma Shanghai Ltd Corp

2022

10.1016/j.cca.2022.05.018

Clinica chimica acta

Clinica chimica acta

ISTP
ISSN：0009-8981
年,卷(期)：2022.532
  • 29